 |
|
|
| |
Efficacy and Safety of Sofosbuvir/Velpatasvir
Plus Ribavirin for 12 or 24 Weeks in Genotype 1 or 2 HCV-infected Japanese Patients with
Prior Treatment Failure to DAA-Based Regimens
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
Namiki Izumi1, Tetsuo Takehara2, Kazuaki Chayama3, Hiroshi Yatsuhashi4, Koichi Takaguchi5, Tatsuya Ide6, Masayuki Kurosaki1, Yoshiyuki Ueno7, Hidenori Toyoda8, Satoru Kakizaki9, Yasuhito Tanaka10, Yoshiiku Kawakami3, Hirayuki Enomoto11, Fusao Ikeda12, Deyuan Jiang13, Shampa De-Oertel13, Brian L. McNabb13, Gregory Camus13, Luisa Stamm13, Diana M. Brainard13, John G. McHutchison13, Satoshi Mochida14, Masashi Mizokami15
1Japanese Red Cross Musashino Hospital, Tokyo, Japan; 2Osaka University Hospital, Osaka, Japan; 3Hiroshima University Hospital, Hiroshima, Japan;
4Nagasaki Medical Center, Nagasaki, Japan; 5Kagawa Prefectural Central Hospital, Kagawa, Japan; 6Kurume University Hospital, Fukuoka, Japan; 7Yamagata University Hospital, Yamagata, Japan; 8Ogaki Municipal Hospital, Gifu, Japan; 9Gunma University Hospital, Gunma, Japan; 10Nagoya City University Hospital, Aichi, Japan; 11Hyogo College of Medicine Hospital, Hyogo, Japan; 12Okayama University Hospital, Okayama, Japan; 13Gilead Sciences, Inc, Foster City, CA; 14Saitama Medical University Hospital, Saitama, Japan; 15National Center for Global Health and Medicine, Chiba, Japan
GT, genotype; HCV, hepatitis C virus; STR, single tablet regimen; SVR12, sustained virologic response 12 weeks after therapy.
1. Jacobson IM, et al. N Engl J Med 2013;368:1867-77; 2. Lawitz E, et al. N Engl J Med 2013;368:1878-87; 3. Lawitz E, et al. J Viral Hepat 2015;22:1011-9; 4. Buggisch P, et al. EASL 2017, abstr SAT-254; 5. Curry M, et al. N Engl J Med 2015;373:2618-28; 6. Curry MP, et al. EASL 2017, abstr PS-102; 7. Feld J, et al. N Engl J Med 2015;373:2599-607; 8. Foster G, et al. N Engl J Med 2015;373:2608-17; 9. Landis C, et al. AASLD 2017, abstr 1096.
|
| |
|
|
|
|
|
